Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.44 |
| ▸ | MEN1 | O00255 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.44 |
| ▸ | NPC1 | O15118 | 8/20 | 0.44 |
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18583755 | 0.90 | KMT2A (0.47) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL17657674 | 0.87 | NPC1 (0.51) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21086890 | 0.87 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22154912 | 0.84 | MEN1 (0.47) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL12476671 | 0.84 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21039222 | 0.84 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29514982 | 0.84 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29918552 | 0.84 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30386326 | 0.84 | KMT2A (0.50) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL18570108 | 0.84 | KMT2A (0.37) | KMT2AMEN1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10361373-B2 | Condensed-cyclic compound and organic light emitting device comprising the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-07-23 | — | — | US | disclosed |
| US-20170062720-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-03-02 | — | — | US | disclosed |
| US-20170062720-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-03-02 | — | — | US | disclosed |
| EP-3135673-A2 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | Samsung Display Co., Ltd. (KR) | 2017-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170062720-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | LRRK2, SLC18A1, CCNT1 | KMT2A 841/4885MEN1 2312/4885SMN1; SMN2 2402/4885 |
| US-10361373-B2 | Condensed-cyclic compound and organic light emitting device comprising the same | LRRK2, SLC18A1, CCNT1 | KMT2A 841/4885MEN1 2312/4885SMN1; SMN2 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.